Matutinović, Marija Sarić (57211507979)Marija Sarić (57211507979)MatutinovićDiana, Tanja (55805191700)Tanja (55805191700)DianaBeleslin, Biljana Nedeljković (6701355427)Biljana Nedeljković (6701355427)BeleslinĆirić, Jasmina (6601995819)Jasmina (6601995819)ĆirićŽarković, Miloš (7003498546)Miloš (7003498546)ŽarkovićBlagojević, Iva Perović (55779522400)Iva Perović (55779522400)BlagojevićKahaly, George J. (7005506174)George J. (7005506174)KahalyIgnjatović, Svetlana (55901270700)Svetlana (55901270700)Ignjatović2025-07-022025-07-022022https://doi.org/10.5937/jomb0-34718https://www.scopus.com/inward/record.uri?eid=2-s2.0-85128942234&doi=10.5937%2fjomb0-34718&partnerID=40&md5=c63859d820f914006d86e43499afbb9chttps://remedy.med.bg.ac.rs/handle/123456789/12176Background: Thyrotropin receptor autoantibodies (TSH-R-Ab) are indispensable biomarkers in the laboratory assessment of thyroid-associated orbitopathy (TAO). Clinical sensitivity of three different assays for TSH-R-Ab determination was evaluated in patients with TAO. Methods: 87 consecutive TAO patients were enrolled and their serum samples analyzed in parallel with three assays. An ECLIA competitive binding and a chemiluminescent bridge immunoassay were used to measure total and binding TSH-R-Ab concentration, while their functional activity was determined using a stimulatory TSH-R-Ab (TSAb) cell-based bioassay. Results: Compared to the two binding assays (ECLIA p<0.001, bridge p=0.003), the TSAb bioassay was more sensitive pertaining to the positive detection of TSH-R-Ab in TAO patients. No difference (p=0.057) was noted between the ECLIA and bridge assays regarding sensitivity rate. All patients with active and/or moderate-to-severe TAO tested positive in the TSAb bioassay (100% and 100%, respectively), while the positivity rates for bridge and ECLIA binding assays were 89.7% and 82.1% for active TAO, and 90.2% and 86.3% for severe TAO, respectively. Negative predictive values of the bioassay, bridge, and ECLIA assays were 100%, 75%, and 71%, respectively for active TAO, and 100%, 86%, and 71%, respectively for moderate-to-severe TAO. The superiority of the bioassay was most prominent in euthyroid (ET) TAO. Positivity rates of the TSAb bioassay, bridge and ECLIA binding assays were 89.6%, 75%, and 64.6%, respectively for inactive TAO; 86.1%, 69.4%, and 52.8%, respectively for mild TAO; 87.5%, 62.5%, and 12.5%, respectively for euthyroid TAO. The bridge assay correlated better with the ECLIA binding assay (r=0.893, p<0.001), compared to the bioassay (r=0.669, p<0.001). Conclusions: In patients with TAO of various activity and severity, the TSAb bioassay demonstrates a superior clinical performance compared to both ECLIA and bridge binding assays. © 2022 Sciendo. All rights reserved.bioassaybridge binding assayECLIA binding assaythyroid-associated orbitopathythyrotropin receptor antibodies